Mark Awad: Our outstanding medical student Malini Gandhi shows that cancers with wild-type RET amplification can also be successfully targeted

Dr. Mark Awad, Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, shared on X (Twitter):

“We know about targeting RET fusion+ lung cancer. Now out in JCO Precision Oncology, our outstanding medical student Malini Gandhi
shows that cancers with wild-type RET amplification can also be successfully targeted with selpercatinib.”

Full article here: Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

Source: Mark Awad / X (Twitter)